Corponi, Filippo http://orcid.org/0000-0002-6807-0617
Anmella, Gerard http://orcid.org/0000-0002-6798-4054
Pacchiarotti, Isabella
Samalin, Ludovic
Verdolini, Norma
Popovic, Dina
Azorin, Jean-Michel
Angst, Jules
Bowden, Charles L.
Mosolov, Sergey http://orcid.org/0000-0002-5749-3964
Young, Allan H. http://orcid.org/0000-0003-2291-6952
Perugi, Giulio
Vieta, Eduard http://orcid.org/0000-0002-0548-0053
Murru, Andrea http://orcid.org/0000-0001-6320-4420
Article History
Received: 20 February 2020
Revised: 7 June 2020
Accepted: 9 June 2020
First Online: 19 July 2020
Conflict of interest
: J.A., F.C., G.A., and N.V. declare no conflict of interest. I.P. has received CME-related honoraria, or consulting fees from ADAMED, Janssen-Cilag, and Lundbeck. L.S. has received grants, honoraria, or consulting fees from Janssen-Cilag, Lundbeck, and Otsuka. D.P. has served as a speaker and/or medical writer for Bristol-Myers Squibb, Merck Sharp & Dohme, Janssen-Cilag, and Ferrer. J.M.A. has received research support and has acted as a consultant and/or served on a speaker’s bureau for Janssen, Lundbeck, Otsuka, Roche, Servier, and Takeda, and reports no financial or other relationship relevant to the subject of this article. C.L.B. has received grant support from Sunovion and the NIMH, and has consulted for Takeda, and reports no financial or other relationship relevant to the subject of this article. S.M. has received research grants from, and been involved in clinical trials for Servier, Eli Lilly, Lundbeck, AstraZeneca, Janssen-Cilag, Sanofi-Aventis, and Geodon Richter and reports no financial or other relationship relevant to the subject of this article. A.H.Y. is honorary Consultant SLaM (NHS, UK). He provided lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Janssen, Lunbeck, Sunovion, Servier, Livanova, and Janssen. He does not share holdings in pharmaceutical companies. He is Lead Investigator for Embolden Study (AZ), BCI Neuroplasticity study and Aripiprazole Mania Study, he did investigator initiated studies from AZ, Eli Lilly, Lundbeck, Wyeth. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK);UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK). He reports no financial or other relationship relevant to the subject of this article. G.P. has acted as consultant of Lundbeck, Angelini, FBHealth. He received grant/research support from Lundbeck and Angelini. He is on the speaker/advisory board of Sanofi-Aventis, Lundbeck, FBHealth, Angelini, and reports no financial or other relationship relevant to the subject of this article. E.V. has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics,Abbott, Allergan, Angelini, AstraZeneca, Bristol-Myers Squibb, Dainippon Sumitomo Pharma, Farmindustria, Ferrer, Forest Research Institute, Gedeon Richter, Glaxo-Smith-Kline, Janssen, Lundbeck, Otsuka, Pfizer, Roche, SAGE, Sanofi-Aventis, Servier, Shire, Sunovion, Takeda, the Brain and Behaviour Foundation, the Spanish Ministry of Science and Innovation (CIBERSAM), the EU Horizon 2020, and the Stanley Medical Research Institute. A.M. has received grants, honoraria, or consulting fees from, Janssen, Lundbeck, and Otsuka.